These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 33355048)

  • 1. Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?
    Grammatiki M; Sagar R; Ajjan RA
    Curr Pharm Des; 2021; 27(8):1061-1067. PubMed ID: 33355048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm.
    Bin Hussain AK; Abdelgadir E; Rashid F; Al Haj A; Thadani P; Bashier AMK
    Diabetes Metab Syndr; 2019; 13(3):1935-1942. PubMed ID: 31235118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach.
    Harrington JL; de Albuquerque Rocha N; Patel KV; Verma S; McGuire DK
    Curr Diab Rep; 2018 Jul; 18(9):64. PubMed ID: 30008022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
    Dunn CJ; Peters DH
    Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ
    Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-benefit assessment of metformin in type 2 diabetes mellitus.
    Howlett HC; Bailey CJ
    Drug Saf; 1999 Jun; 20(6):489-503. PubMed ID: 10392666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
    Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
    Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.
    Inzucchi SE
    Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.